Logo image of GRAY

GRAYBUG VISION INC (GRAY) Stock Fundamental Analysis

NASDAQ:GRAY - US38942Q1031 - Common Stock

5.5 USD
-0.67 (-10.8%)
Last: 3/20/2023, 8:12:53 PM
6.51 USD
+1.01 (+18.36%)
After Hours: 3/20/2023, 8:12:53 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GRAY. GRAY was compared to 193 industry peers in the Pharmaceuticals industry. GRAY has a great financial health rating, but its profitability evaluates not so good. GRAY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GRAY had negative earnings in the past year.
In the past year GRAY has reported a negative cash flow from operations.
GRAY had negative earnings in each of the past 5 years.
GRAY had a negative operating cash flow in each of the past 5 years.
GRAY Yearly Net Income VS EBIT VS OCF VS FCFGRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for GRAY are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GRAY Yearly ROA, ROE, ROICGRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRAY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GRAY Yearly Profit, Operating, Gross MarginsGRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, GRAY has more shares outstanding
There is no outstanding debt for GRAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GRAY Yearly Shares OutstandingGRAY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 5M 10M 15M 20M
GRAY Yearly Total Debt VS Total AssetsGRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -8.80, we must say that GRAY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of GRAY (-8.80) is worse than 76.92% of its industry peers.
There is no outstanding debt for GRAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.8
ROIC/WACCN/A
WACCN/A
GRAY Yearly LT Debt VS Equity VS FCFGRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 10.72 indicates that GRAY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 10.72, GRAY belongs to the top of the industry, outperforming 83.71% of the companies in the same industry.
A Quick Ratio of 10.72 indicates that GRAY has no problem at all paying its short term obligations.
The Quick ratio of GRAY (10.72) is better than 83.71% of its industry peers.
Industry RankSector Rank
Current Ratio 10.72
Quick Ratio 10.72
GRAY Yearly Current Assets VS Current LiabilitesGRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.70% over the past year.
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.89% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GRAY Yearly Revenue VS EstimatesGRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 100M 200M 300M
GRAY Yearly EPS VS EstimatesGRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRAY. In the last year negative earnings were reported.
Also next year GRAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GRAY Price Earnings VS Forward Price EarningsGRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GRAY Per share dataGRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 200 -200 300

4.3 Compensation for Growth

GRAY's earnings are expected to grow with 13.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.89%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GRAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRAYBUG VISION INC

NASDAQ:GRAY (3/20/2023, 8:12:53 PM)

After market: 6.51 +1.01 (+18.36%)

5.5

-0.67 (-10.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-09 2023-03-09
Earnings (Next)05-08 2023-05-08
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners146.19%
Ins Owner Change0%
Market Cap617.26K
Analysts43.33
Price Target42.84 (678.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2.5%
Min EPS beat(2)-2.5%
Max EPS beat(2)-2.5%
EPS beat(4)1
Avg EPS beat(4)-6.08%
Min EPS beat(4)-23.06%
Max EPS beat(4)7.33%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1100%
PT rev (3m)1100%
EPS NQ rev (1m)-58.7%
EPS NQ rev (3m)-58.7%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.02
P/tB 0.02
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-206.6
FCFYN/A
OCF(TTM)-203.86
OCFYN/A
SpS0
BVpS320.51
TBVpS320.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.12%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.72
Quick Ratio 10.72
Altman-Z -8.8
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)146.72%
Cap/Depr(5y)290.92%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.81%
EPS Next Y5.14%
EPS Next 2Y13.89%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y7.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.37%
OCF growth 3YN/A
OCF growth 5YN/A